

## **Hodgkin's Lymphoma Treatment Market Report and Forecast 2024-2032**

Market Report | 2024-09-30 | 250 pages | EMR Inc.

### **AVAILABLE LICENSES:**

- Single User License \$4999.00
- Five User License \$5999.00
- Corporate License \$6999.00

### **Report description:**

Hodgkin's Lymphoma Treatment Market Report and Forecast 2024-2032??

The Hodgkin's lymphoma treatment market reached a value of about USD 1.41 billion in 2023. The market is expected to grow at a CAGR of 13.20% during the period 2024-2032, reaching around USD 4.31 billion by 2032. This growth is driven by advancements in treatment modalities, increasing incidence of Hodgkin's lymphoma, and rising awareness about early diagnosis and treatment, alongside supportive government policies and healthcare investments.

### Hodgkin's Lymphoma Treatment Market- Analysis

The Hodgkin's lymphoma treatment market is experiencing substantial growth due to advancements in medical technologies and the increasing use of targeted therapies and immunotherapies. These treatments are critical for improving patient outcomes and are essential in various therapeutic protocols aimed at managing Hodgkin's lymphoma. The rising incidence of the disease, along with enhanced early diagnosis and treatment strategies, is further driving market growth, making Hodgkin's lymphoma treatments a crucial component of modern cancer care.

### Market Driver

**Technological Advancements:** Continuous innovation in treatment technologies has significantly enhanced the effectiveness and safety of Hodgkin's lymphoma therapies. These advancements are driving market growth as healthcare providers seek more reliable and efficient treatment solutions. Improved drug formulations, targeted therapies, and advanced radiation techniques are making Hodgkin's lymphoma treatments more effective and appealing for clinical use.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Increasing Incidence of Hodgkin's Lymphoma:** The rising incidence of Hodgkin's lymphoma globally is driving the demand for effective treatment options. Early diagnosis and increased awareness about the disease are leading to higher treatment rates. The growing elderly population, which is more susceptible to various cancers, including Hodgkin's lymphoma, is also contributing to the increased demand for treatment therapies.

**Supportive Government Policies:** Government initiatives and funding are promoting research and development in the field of oncology. Supportive policies and financial incentives for innovation in cancer treatment are contributing to market growth, making advanced therapies more accessible. Government support is also facilitating faster approval and adoption of new treatment options for Hodgkin's lymphoma.

**Rising Awareness and Screening Programs:** Increased awareness about Hodgkin's lymphoma and the importance of early screening are driving market growth. Public health campaigns and screening programs are enhancing the detection rates of Hodgkin's lymphoma, leading to timely and effective treatment interventions. This trend is contributing to improved patient outcomes and supporting market expansion.

### Market Challenges

**High Costs:** The high cost of Hodgkin's lymphoma treatments, including chemotherapy, radiotherapy, and targeted therapies, can limit accessibility, especially in low-income regions. This financial barrier is a significant challenge for widespread adoption of advanced treatment modalities. Efforts to reduce costs and improve affordability are essential to expanding market reach and ensuring that more patients can benefit from these therapies.

**Regulatory Hurdles:** Stringent regulatory requirements for the approval and certification of new treatments can delay market entry and increase development costs. These regulatory challenges can be significant obstacles for manufacturers aiming to introduce innovative therapies. Navigating complex regulatory landscapes and ensuring compliance with varying international standards are critical to bringing new treatment options to market efficiently.

**Potential Side Effects:** The potential side effects and complications associated with Hodgkin's lymphoma treatments, such as toxicity from chemotherapy and radiotherapy, pose challenges to their use. Ensuring patient safety and addressing these concerns through research and improved treatment protocols are crucial for market growth. Continuous monitoring and post-market surveillance are necessary to mitigate these risks and maintain the trust of healthcare providers and patients.

**Limited Awareness in Developing Regions:** The limited awareness and understanding of Hodgkin's lymphoma and its treatments in developing regions can hinder market growth. Increasing knowledge about the disease and available treatment options through educational initiatives is essential to promoting wider adoption and integration into standard medical practices.

### Future Opportunities

**Emerging Markets:** Expanding into emerging markets with improving healthcare infrastructure presents substantial growth opportunities. These regions offer untapped potential for increasing access to Hodgkin's lymphoma treatments and improving patient outcomes. Strategic investments and partnerships in these areas can drive market growth and enhance the availability of reliable therapies.

**Development of Novel Therapies:** The development of novel therapies, including targeted therapies and immunotherapies, can

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

enhance the effectiveness and safety of Hodgkin's lymphoma treatments. Innovations in treatment modalities are expected to drive market growth by providing more targeted and efficient solutions. New therapies that reduce the risk of side effects and improve patient outcomes can expand the use of Hodgkin's lymphoma treatments.

**Collaborations and Partnerships:** Strategic partnerships between pharmaceutical companies, research institutions, and healthcare providers can drive market expansion. Collaborations can facilitate research, development, and distribution efforts, enhancing the availability and quality of Hodgkin's lymphoma treatments. Joint ventures and alliances are essential for leveraging expertise and resources to innovate and expand market offerings.

**Integration with Advanced Diagnostic Technologies:** Incorporating advanced diagnostic technologies, such as molecular diagnostics and genetic profiling, can enhance the precision and personalization of Hodgkin's lymphoma treatments. These innovations can drive market growth by providing more accurate and tailored treatment solutions. The integration of advanced diagnostics can also improve patient outcomes and streamline treatment protocols.

### Hodgkin's Lymphoma Treatment Market Trends

**Rising Adoption of Targeted Therapies:** The adoption of targeted therapies for Hodgkin's lymphoma is increasing due to their effectiveness in selectively targeting cancer cells. This trend is driving market growth as more healthcare providers incorporate targeted therapies into their treatment protocols. The positive outcomes associated with targeted therapies are encouraging wider adoption in clinical practice.

**Focus on Immunotherapies:** There is a growing trend towards the use of immunotherapies in Hodgkin's lymphoma treatment. This focus on harnessing the body's immune system to fight cancer is enhancing patient care and supporting market growth. Immunotherapies are becoming more popular due to their ability to improve survival rates and reduce side effects compared to traditional treatments.

**Increased Investment in R&D:** Investment in research and development for Hodgkin's lymphoma treatments is on the rise. Companies are dedicating significant resources to discovering new therapies and improving existing treatments, fostering innovation in the market. Enhanced R&D efforts are expected to yield advanced treatment solutions that offer better efficacy and safety profiles.

**Emphasis on Patient-Centered Care:** Ensuring patient-centered care in Hodgkin's lymphoma treatment is a top priority. Advances in treatment protocols and supportive care measures are enhancing the quality of life for patients, supporting market growth. The emphasis on holistic patient care is expected to continue driving innovation and adoption in the Hodgkin's lymphoma treatment market.

### Hodgkin's Lymphoma Treatment Market Segmentation

#### Market Breakup by Type

Classical Hodgkin Lymphoma

Nodular Lymphocyte-Hodgkin Lymphoma

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

The Hodgkin's lymphoma treatment market is segmented by type into classical hodgkin lymphoma and nodular lymphocyte-predominant hodgkin lymphoma. Classical hodgkin lymphoma is the more common type and drives a significant portion of the market due to its higher prevalence. Nodular lymphocyte-predominant hodgkin lymphoma, while less common, requires specific treatment approaches, contributing to the market's diversity and growth.

#### Market Breakup by Treatment

Chemotherapy

Radiotherapy

Others

The market is segmented by treatment into chemotherapy, radiotherapy, and others. Chemotherapy and radiotherapy are the primary treatment modalities for Hodgkin's lymphoma, with chemotherapy being the most used. The growing use of other treatments, such as targeted therapies and immunotherapies, highlights the expanding scope of treatment options and contributes to overall market growth.

#### Market Breakup by Region

United States

EU-4 and the United Kingdom

Germany

France

Italy

Spain

United Kingdom

Japan

India

The Hodgkin's lymphoma treatment market is segmented by region into the United States, EU-4 (Germany, France, Italy, Spain) and the United Kingdom, Japan, and India. The United States and EU-4 countries lead the market due to advanced healthcare infrastructure and high adoption of new treatment modalities. Japan and India are emerging as significant growth areas, driven by improving healthcare access and increasing awareness about cancer treatments. These regions offer substantial opportunities for market expansion and the introduction of innovative therapies.

#### Hodgkin's Lymphoma Treatment Market Competitive Landscape

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

The Hodgkin's lymphoma treatment market features several key players actively shaping the competitive landscape. Notable companies include Alkem Laboratories Ltd., Baxter International Inc., Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Incyte Corp., Merck & Co. Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, AstraZeneca Plc., Bayer AG, Novartis AG, Gilead Sciences, Inc., Spectrum Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., and Janssen Pharmaceuticals, Inc. These companies engage in activities such as mergers and acquisitions, research initiatives, product introductions, and strategic partnerships to expand their market presence and capabilities. These activities drive innovation and growth within the Hodgkin's lymphoma treatment market, ensuring continuous improvement and broadening service offerings.

#### Key Questions Answered in the Report

What is the expected CAGR of the Hodgkin's lymphoma treatment market during the forecast period 2024-2032?

How are advancements in medical technologies driving the growth of the Hodgkin's lymphoma treatment market?

What role do target therapies and immunotherapies play in the market's expansion?

How does the increasing incidence of Hodgkin's lymphoma impact the demand for treatment options?

What are the key factors contributing to the growth of the Hodgkin's lymphoma treatment market in the United States and EU-4 countries?

How do supportive government policies influence the adoption of advanced Hodgkin's lymphoma treatment?

What challenges are associated with the high costs of Hodgkin's lymphoma treatment, and how are they being addressed?

How do stringent regulatory requirements affect the introduction of new treatment options in the market?

What opportunities exist for expanding Hodgkin's lymphoma treatment into emerging markets?

How can the development of novel therapies drive market growth for Hodgkin's lymphoma treatment?

What are the benefits of integrating advanced diagnostic technologies with Hodgkin's lymphoma treatment?

How are strategic partnerships and collaborations influencing research and development in the Hodgkin's lymphoma treatment market?

#### Key Benefits for Stakeholders

The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the Hodgkin's lymphoma treatment market from 2017-2032.

The research report provides the latest information on the market drivers, challenges, and opportunities in the Hodgkin's lymphoma treatment market.

The study maps the leading, as well as the fastest-growing, regional markets, enabling stakeholders to identify key country-level markets within each region.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the Hodgkin's lymphoma treatment industry and its attractiveness.

The competitive landscape section allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.

**Table of Contents:**

- 1 Preface
  - 1.1 Objectives of the Study
  - 1.2 Key Assumptions
  - 1.3 Report Coverage - Key Segmentation and Scope
  - 1.4 Research Methodology
- 2 Executive Summary
- 3 Hodgkin's Lymphoma Treatment Market Overview: 8 Major Market
  - 3.1 Hodgkin's Lymphoma Treatment Market Historical Value (2017-2023)
  - 3.2 Hodgkin's Lymphoma Treatment Market Forecast Value (2024-2032)
- 4 Vendor Positioning Analysis
  - 4.1 Key Vendors
  - 4.2 Prospective Leaders
  - 4.3 Niche Leaders
  - 4.4 Disruptors
- 5 Diabetic Retinopathy: Disease Overview
  - 5.1 Guidelines and Stages
  - 5.2 Pathophysiology
  - 5.3 Screening and Diagnosis
  - 5.4 Therapy Pathway
- 6 Patient Profile
  - 6.1 Patient Profile Overview

- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Therapy Success Rate
- 7 Hodgkin's Lymphoma Treatment Market Epidemiology Scenario and Forecast - 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2017-2032)
  - 7.1.1 Prevalence, by Country
    - 7.1.1.1 U.S.
    - 7.1.1.2 U.K.
    - 7.1.1.3 EU4
    - 7.1.1.4 India
    - 7.1.1.5 Japan
  - 7.1.2 Mortality by Country
    - 7.1.2.1 U.S.
    - 7.1.2.2 U.K.
    - 7.1.2.3 EU4
    - 7.1.2.4 India
    - 7.1.2.5 Japan
  - 7.1.3 Treatment Seeking Rate by Country
    - 7.1.3.1 U.S.
    - 7.1.3.2 U.K.
    - 7.1.3.3 EU4
    - 7.1.3.4 India
    - 7.1.3.5 Japan
- 8 Hodgkin's Lymphoma Treatment Market Landscape: 8 Major Market\*
  - 8.1 Hodgkin's Lymphoma Treatment Market: Developers Landscape
    - 8.1.1 Analysis by Year of Establishment
    - 8.1.2 Analysis by Company Size
    - 8.1.3 Analysis by Region
  - 8.2 Hodgkin's Lymphoma Treatment Market: Product Landscape
    - 8.2.1 Analysis by Type
    - 8.2.2 Analysis by Treatment
- 9 Hodgkin's Lymphoma Treatment Market Challenges and Unmet Needs
  - 9.1 Therapy Pathway Challenges
  - 9.2 Compliance and Drop-Out Analysis
  - 9.3 Awareness and Prevention Gaps
- 10 Cost of Therapy
- 11 Hodgkin's Lymphoma Treatment: Market Dynamics
  - 11.1 Market Drivers and Constraints
  - 11.2 SWOT Analysis
    - 11.2.1 Strengths
    - 11.2.2 Weaknesses
    - 11.2.3 Opportunities
    - 11.2.4 Threats
  - 11.3 PESTEL Analysis
    - 11.3.1 Political
    - 11.3.2 Economic
    - 11.3.3 Social
    - 11.3.4 Technological

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.3.5□Legal
- 11.3.6□Environment
- 11.4□Porter's Five Forces Model
- 11.4.1□Bargaining Power of Suppliers
- 11.4.2□Bargaining Power of Buyers
- 11.4.3□Threat of New Entrants
- 11.4.4□Threat of Substitutes
- 11.4.5□Degree of Rivalry
- 11.5□Key Demand Indicators
- 11.6□Key Price Indicators
- 11.7□Industry Events, Initiatives, and Trends
- 11.8□Value Chain Analysis
- 12□Hodgkin's Lymphoma Treatment Market Segmentation: 8 Major Markets
- 12.1□Hodgkin's Lymphoma Treatment Market by Type
- 12.1.1□Market Overview
- 12.1.2□Classical Hodgkin Lymphoma
- 12.1.3□Nodular Lymphocyte-Hodgkin Lymphoma
- 12.2□Hodgkin's Lymphoma Treatment Market by Treatment
- 12.2.1□Market Overview
- 12.2.2□Chemotherapy
- 12.2.3□Radiotherapy
- 12.2.4□Others
- 12.3□Hodgkin's Lymphoma Treatment Market by Region
- 12.3.1□Market Overview
- 12.3.2□United States
- 12.3.3□EU-4 and the United Kingdom
- 12.3.3.1□Germany
- 12.3.3.2□France
- 12.3.3.3□Italy
- 12.3.3.4□Spain
- 12.3.3.5□United Kingdom
- 12.3.4□Japan
- 12.3.5□India
- 13□United States Hodgkin's Lymphoma Treatment Market (2017-2032)
- 13.1□United States Hodgkin's Lymphoma Treatment Market Historical Value (2017-2023)
- 13.2□United States Hodgkin's Lymphoma Treatment Market Forecast Value (2024-2032)
- 13.3□United States Hodgkin's Lymphoma Treatment Market by Type
- 13.3.1□Market Overview
- 13.3.2□Classical Hodgkin Lymphoma
- 13.3.3□Nodular Lymphocyte-Hodgkin Lymphoma
- 13.4□United States Hodgkin's Lymphoma Treatment Market by Treatment
- 13.4.1□Market Overview
- 13.4.2□Chemotherapy
- 13.4.3□Radiotherapy
- 13.4.4□Others
- 14□EU-4 and United Kingdom Hodgkin's Lymphoma Treatment Market (2017-2032)
- 14.1□EU-4 and United Kingdom Hodgkin's Lymphoma Treatment Market Historical Value (2017-2023)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)



- 14.2 EU-4 and United Kingdom Hodgkin's Lymphoma Treatment Market Forecast Value (2024-2032)
- 14.3 EU-4 and United Kingdom Hodgkin's Lymphoma Treatment Market by Type
  - 14.3.1 Market Overview
  - 14.3.2 Classical Hodgkin Lymphoma
  - 14.3.3 Nodular Lymphocyte-Hodgkin Lymphoma
- 14.4 EU-4 and United Kingdom Hodgkin's Lymphoma Treatment Market by Treatment
  - 14.4.1 Market Overview
  - 14.4.2 Chemotherapy
  - 14.4.3 Radiotherapy
  - 14.4.4 Others
- 15 Japan Hodgkin's Lymphoma Treatment Market
  - 15.1 Japan Hodgkin's Lymphoma Treatment Market Historical Value (2017-2023)
  - 15.2 Japan Hodgkin's Lymphoma Treatment Market Forecast Value (2024-2032)
  - 15.3 Japan Hodgkin's Lymphoma Treatment Market by Type
    - 15.3.1 Market Overview
    - 15.3.2 Classical Hodgkin Lymphoma
    - 15.3.3 Nodular Lymphocyte-Hodgkin Lymphoma
  - 15.4 Japan Hodgkin's Lymphoma Treatment Market by Treatment
    - 15.4.1 Market Overview
    - 15.4.2 Chemotherapy
    - 15.4.3 Radiotherapy
    - 15.4.4 Others
- 16 India Hodgkin's Lymphoma Treatment Market
  - 16.1 India Hodgkin's Lymphoma Treatment Market Historical Value (2017-2023)
  - 16.2 India Hodgkin's Lymphoma Treatment Market Forecast Value (2024-2032)
  - 16.3 India Hodgkin's Lymphoma Treatment Market by Type
    - 16.3.1 Market Overview
    - 16.3.2 Classical Hodgkin Lymphoma
    - 16.3.3 Nodular Lymphocyte-Hodgkin Lymphoma
  - 16.4 India Hodgkin's Lymphoma Treatment Market by Treatment
    - 16.4.1 Market Overview
    - 16.4.2 Chemotherapy
    - 16.4.3 Radiotherapy
    - 16.4.4 Others
- 17 Regulatory Framework
  - 17.1 Regulatory Overview
  - 17.2 US FDA
  - 17.3 EU EMA
  - 17.4 INDIA CDSCO
  - 17.5 JAPAN PMDA
  - 17.6 Others
- 18 Patent Analysis
  - 18.1 Analysis by Type of Patent
  - 18.2 Analysis by Publication Year
  - 18.3 Analysis by Issuing Authority
  - 18.4 Analysis by Patent Age
  - 18.5 Analysis by CPC Analysis

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 18.6□ Analysis by Patent Valuation
- 18.7□ Analysis by Key Players
- 19□ Clinical Trial Analysis
- 19.1□ Analysis by Trial Registration Year
- 19.2□ Analysis by Trial Status
- 19.3□ Analysis by Trial Phase
- 19.4□ Analysis by Therapeutic Area
- 19.5□ Analysis by Geography
- 20□ Grant Analysis
- 20.1□ Analysis by Year
- 20.2□ Analysis by Amount Awarded
- 20.3□ Analysis by Issuing Authority
- 20.4□ Analysis by Grant Product
- 20.5□ Analysis by Funding Institute
- 20.6□ Analysis by Departments
- 20.7□ Analysis by Recipient Organization
- 21□ Strategic Initiatives
- 21.1□ Analysis by Partnership Instances
- 21.2□ Analysis by Type of Partnership
- 21.3□ Analysis by Leading Players
- 21.4□ Analysis by Geography
- 22□ Supplier Landscape
- 22.1□ Market Share by Top 5 Companies
- 22.2□ Alkem Laboratories Ltd .
- 22.2.1□ Financial Analysis
- 22.2.2□ Product Portfolio
- 22.2.3□ Demographic Reach and Achievements
- 22.2.4□ Company News and Developments
- 22.2.5□ Certifications
- 22.3□ Baxter International Inc
- 22.3.1□ Financial Analysis
- 22.3.2□ Product Portfolio
- 22.3.3□ Demographic Reach and Achievements
- 22.3.4□ Company News and Developments
- 22.3.5□ Certifications
- 22.4□ Biogen Inc .
- 22.4.1□ Financial Analysis
- 22.4.2□ Product Portfolio
- 22.4.3□ Demographic Reach and Achievements
- 22.4.4□ Company News and Developments
- 22.4.5□ Certifications
- 22.5□ Bristol-Myers Squibb Company
- 22.5.1□ Financial Analysis
- 22.5.2□ Product Portfolio
- 22.5.3□ Demographic Reach and Achievements
- 22.5.4□ Company News and Developments
- 22.5.5□ Certifications

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

22.6 F Hoffmann-La Roche Ltd  
22.6.1 Financial Analysis  
22.6.2 Product Portfolio  
22.6.3 Demographic Reach and Achievements  
22.6.4 Company News and Developments  
22.6.5 Certifications  
22.7 Incyte Corp .  
22.7.1 Financial Analysis  
22.7.2 Product Portfolio  
22.7.3 Demographic Reach and Achievements  
22.7.4 Company News and Developments  
22.7.5 Certifications  
22.8 Merck & Co. Inc .  
22.8.1 Financial Analysis  
22.8.2 Product Portfolio  
22.8.3 Demographic Reach and Achievements  
22.8.4 Company News and Developments  
22.8.5 Certifications  
22.9 Pfizer Inc .  
22.9.1 Financial Analysis  
22.9.2 Product Portfolio  
22.9.3 Demographic Reach and Achievements  
22.9.4 Company News and Developments  
22.9.5 Certifications  
22.10 Takeda Pharmaceutical Company Limited  
22.10.1 Financial Analysis  
22.10.2 Product Portfolio  
22.10.3 Demographic Reach and Achievements  
22.10.4 Company News and Developments  
22.10.5 Certifications  
22.11 AstraZeneca Plc .  
22.11.1 Financial Analysis  
22.11.2 Product Portfolio  
22.11.3 Demographic Reach and Achievements  
22.11.4 Company News and Developments  
22.11.5 Certifications  
22.12 Bayer AG  
22.12.1 Financial Analysis  
22.12.2 Product Portfolio  
22.12.3 Demographic Reach and Achievements  
22.12.4 Company News and Developments  
22.12.5 Certifications  
22.13 Novartis AG  
22.13.1 Financial Analysis  
22.13.2 Product Portfolio  
22.13.3 Demographic Reach and Achievements  
22.13.4 Company News and Developments

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 22.13.5□Certifications
- 22.14□Gilead Sciences, Inc .
  - 22.14.1□Financial Analysis
  - 22.14.2□Product Portfolio
  - 22.14.3□Demographic Reach and Achievements
  - 22.14.4□Company News and Developments
  - 22.14.5□Certifications
- 22.15□Spectrum Pharmaceuticals, Inc .
  - 22.15.1□Financial Analysis
  - 22.15.2□Product Portfolio
  - 22.15.3□Demographic Reach and Achievements
  - 22.15.4□Company News and Developments
  - 22.15.5□Certifications
- 22.16□Teva Pharmaceutical Industries Ltd .
  - 22.16.1□Financial Analysis
  - 22.16.2□Product Portfolio
  - 22.16.3□Demographic Reach and Achievements
  - 22.16.4□Company News and Developments
  - 22.16.5□Certifications
- 22.17□Janssen Pharmaceuticals, Inc .
  - 22.17.1□Financial Analysis
  - 22.17.2□Product Portfolio
  - 22.17.3□Demographic Reach and Achievements
  - 22.17.4□Company News and Developments
  - 22.17.5□Certifications
- 23□Hodgkin's Lymphoma Treatment Market - Distribution Model (Additional Insight)
  - 23.1□Overview
  - 23.2□Potential Distributors
  - 23.3□Key Parameters for Distribution Partner Assessment
- 24□Key Opinion Leaders (KOL) Insights (Additional Insight)
- 25□Payment Methods (Additional Insight)
  - 25.1□Government Funded
  - 25.2□Private Insurance
  - 25.3□Out-of-Pocket

\*Additional insights provided are customisable as per client requirements.

\* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

\*\*The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

## Hodgkin's Lymphoma Treatment Market Report and Forecast 2024-2032

Market Report | 2024-09-30 | 250 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

### ORDER FORM:

Select license	License	Price
	Single User License	\$4999.00
	Five User License	\$5999.00
	Corporate License	\$6999.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ \*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-11"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com